English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, July 9, 2025
エーザイ、厚生労働省の中央社会保険医療協議会による「レケンビ」の費用対効果評価について
Tuesday, July 8, 2025
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
エーザイ、CDP から「サプライヤー・エンゲージメント評価」において最高評価である「サプライヤー・エンゲージメント・リーダー」に選定
Monday, June 2, 2025
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
エーザイ、国内 OTC 医薬品初となるプロトンポンプ阻害薬「パリエット(R) S」新発売
Monday, June 3, 2024
エーザイ、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向けたベンチャー投資事業を強化
Tuesday, May 28, 2024
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea
Thursday, May 23, 2024
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
Wednesday, May 22, 2024
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan
Wednesday, May 15, 2024
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575